-
Mashup Score: 1Webprogram Unavailable - 2 year(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Webprogram Unavailable - 2 year(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Impact of Chromosome 1 Abnormalities Among Pts w/ Newly Diagnosed Multiple Myeloma: A Subgroup Analysis from the Endurance (#EAonc E1A11) Trial [oral: 12/12/21] @TMSchmidtMD et al. @myelomaMD @eaonc Abstract 467 #ASH21 https://t.co/HaaZ5tEEPT #NCT01863550 #mmsm #PrecisionMedicine https://t.co/d0BsgfmYTl
-
-
Mashup Score: 2FISH and WGS in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma - WGS Will Affect Future Treatment Decisions - 2 year(s) ago
Abstract. Background:FISH is the gold standard for genetic characterization and risk stratification of multiple myeloma (MM) at diagnosis. Retrospective studies
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
FISH and WGS in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma โ WGS Will Affect Future Treatment Decisions [Oral: 12/12/21] Marietta Truger et al. MLL Munich Leukemia Laboratory Abst 397 #ASH21 https://t.co/F1Z0Ehl26K #mmsm #cagenome #PrecisionMedicine https://t.co/RRF6bK1hca
-
-
Mashup Score: 0The Multiple Myeloma Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/xMuZ5oscgU Thanks to @power4patients @BMS_Myeloma_US @IMFjimMYELOMA #myeloma #ash21
-
-
Mashup Score: 1The Multiple Myeloma Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/C3iVWMSfP0 Thanks to @RahulBanerjeeMD @healthtreeforMM #mmsm #ash21
-
-
Mashup Score: 0Webprogram Unavailable - 2 year(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RCT of Primary Prophylaxis w/ Weekly Alendronate Against Glucocorticoid-Induced Osteoporosis in Lymphoma Pts Treated w/ Steroid-Containing Chemotherapy [Dec 12, 2021] Jensen et al. Abstract 456 #ASH21 https://t.co/5hoV9HpqQh #lymsm #BoneHealth #SuppOnc HT @graham74GC https://t.co/6C5zfIc4Ay
-
-
Mashup Score: 0Recommendation on Advanced Molecular Testing in Hematolymphoid Malignancies in the Veterans Population - 2 year(s) ago
Abstract. The Veterans Health Administration is the largest integrated provider of cancer services in the nation, with approximately 50,000 new cancer cases dia
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Recommendation on Advanced Molecular Testing in Hematolymphoid Malignancies in the Veterans Population [Nov 5, 2021] Neff, et al. #ASH21 Abstract 4983 https://t.co/GrnqmcA0gE #PrecisionMedicine https://t.co/SQcT8SOhXq
-
-
Mashup Score: 4TRANSFORM: Liso-cel vs SoC for second-line treatment of LBCL - 2 year(s) ago
Lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy, vs SOC with salvage chemotherapy followed by ASCT as 2L treatments in patients with R/R LBCL: Results from the randomized phase 3 TRANSFORM study.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
๐ In case you missed it! ๐ The anti-CD19 CAR T liso-cel improves survival vs SoC as 2L treatment in R/R LBCL. See an overview of the phase III TRANSFORM data presented at #ASH21 ๐ https://t.co/yDZZN8EKsu ๐ #lymsm #lymphoma https://t.co/nR6IDG1wkS
-
-
Mashup Score: 5Survival outcomes in older patients receiving CPX-351 versus HMA + venetoclax as frontline AML therapy - 2 year(s) ago
New frontline therapy options have recently improved the acute myeloid leukemia (AML) treatment landscape for older patients, including the liposomal formulation of daunorubicin and cytarabine (CPX-351) and hypomethylating agent (HMA) + venetoclax (HMA + Ven) combination. CPX-351 is approved by the U.S.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
๐Have you read our summary? ๐CPX-351 and HMA + venetoclax have been used to treat similar cohorts of pts with #AML. The first real-world comparison of survival outcomes achieved with these therapies from #ASH21 ๐ ๐ https://t.co/o8FARHDnKg ๐ #AMLsm #leukemia #leusm https://t.co/n7Zi0eZGhi
-
-
Mashup Score: 7
In order to address these educational needs, this CME-certified activity will focus on key studies presented at ASH 2021; including results from the Graaph-2014 (studied the omission of HD-AraC during consolidation of Ph-positive ALL patients treated with nilotinib and low-intensity chemotherapy) an
Source: Current ActivitiesCategories: Hematologists1, Latest HeadlinesTweet-
12/ โ ๏ธ Donโt forget to claim your ๐ #CME @AmerMedicalAssn credit ๐ซ https://t.co/A1WhTSz40N Thank you for joining our #ALL #leukemia CME series w/ @BonumCe ๐
-
3/ ๐#CME credit provided by @IntegrityCE ๐คIn partnership w/ @BonumCe โฑ๏ธ Please answer! โฑ๏ธ ๐ข PRE-polls before ๐ฌ ๐ดPOST-polls after ๐ฌ ๐ or๐ https://t.co/A1WhTSz40N for #CME โน๏ธ ๐CME info ๐ https://t.co/j8q5GjQwxX
-
2/๐ Get your ๐ #CME CME โน๏ธ๐ https://t.co/A1WhTSz40N #MedTwitter #OncTwitter #leusm โ๏ธWhat are your credentialsโ
-
๐ฅ #leukemia #ASH21 ๐๏ธ Last call for poster #๏ธ5๏ธ ใฐ๏ธ Graaph-2014 study โ adding Nelarabine to chemo for #ALL pts ๐น #OncTwitter w/ @LoriMuffly & @LuskinMarlise ๐ธ#CME from @BonumCe ๐https://t.co/A1WhTSQESl ๐ธSupported by edu grant Jazz Pharma https://t.co/W2TZi6C1IV
-
Pathogenic Germline Variants in Multiple Myeloma [Dec 12, 2021] @SantiagoThibaud et al. Abstract 399 #ASH21 https://t.co/OmrR1Mb4Oq #mmsm #cagenome @theMMRF https://t.co/wmgv4IE7Dn